XTLB : Summary for XTL Biopharmaceuticals Ltd. - Yahoo Finance

U.S. Markets close in 6 hrs 14 mins

XTL Biopharmaceuticals Ltd. (XTLB)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.60+0.13 (+5.26%)
As of 9:44AM EDT. Market open.
People also watch
ZSANMBRXMYOSBNTCOCRX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.47
Open2.61
Bid2.25 x 100
Ask2.65 x 300
Day's Range2.59 - 2.61
52 Week Range0.51 - 4.70
Volume2,900
Avg. Volume128,204
Market Cap7.07M
Beta0.26
PE Ratio (TTM)-2.00
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire7 days ago

    XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing Investors

    XTL Biopharmaceuticals Ltd. (XTLB) (XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that it has closed its private offering of securities for proceeds of $2.8 million. In connection with the offering, announced previously on March 7, 2017, the Company issued and sold 1,400,000 American Depository Shares (ADSs) at a purchase price of $2.00 per ADS. The Company has agreed to hold a shareholder meeting to increase its authorized ordinary shares to allow for the full exercise of the warrants (the "Authorized Capital Increase").

  • PR Newswire22 days ago

    XTL Biopharmaceuticals Announces $2.8 Million Private Placement From Existing Investors

    XTL Biopharmaceuticals Ltd. (XTLB) (XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that it has entered into definitive agreements with existing investors to receive proceeds of $2.8 million in a private placement offering. In connection with the offering, the Company will issue 1,400,000 American Depository Shares (ADSs) at a purchase price of $2.00 per ADS, one cent below yesterday's closing price.  Additionally, for each ADS purchased by investors, the investors will receive an unregistered warrant to purchase one ADS.  The Company has agreed to hold a shareholder meeting to increase its authorized ordinary shares to allow for the full exercise of the warrants (the "Authorized Capital Increase").

  • PR Newswire28 days ago

    XTL Biopharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement

    As previously disclosed on November 14, 2017, XTL received a letter from Nasdaq notifying the Company that it was not in compliance with Nasdaq's Listing Rule 5450(a)(1) because the minimum bid price of the Company's American Depositary Shares ("ADSs") had closed below US $1.00 per share for 30 consecutive business days. On February 28, 2017, XTL received notification from Nasdaq that the closing price of the Company's America Depository Share has been at $1.00 per share or greater for the last 10 consecutive business days from February 10 through 24, 2017.